Home
Custom Pages
Portfolio

Global Leader In Drug Discovery of the WNT Pathway

Curegenix Corporation

Curegenix is a clinical-stage company with operations in the San Francisco Bay Area and Guangzhou China. We focus on the discovery and development of novel drugs targeting the WNT signaling pathway for cancer and tissue repair/regeneration. Our lead candidate CGX1321 has successfully completed phase I dose-escalation clinical trials in the US and China, and entered into a phase Ib Pembrolizumab combination study in collaboration with Merck.

Collaborators

Drug Discovery

The company has R&D and management teams in Guangzhou, China and San Francisco, USA. There are 500 square meters of experimental and office space in Guangzhou, with 10,000-level cell rooms and SPF-level animal rooms, which can carry out in vivo and in vitro screening, drug-making research and exploratory toxicological research. The company also makes full use of domestic perfect and high-quality CRO service companies to further promote the pre-clinical research and development of new drugs, and complete the Sino-US IND double report of the project.

Curegenix is a clinical-stage company with operations in the San Francisco Bay Area and Guangzhou China. We focus on the discovery and development of novel drugs.

Get In Touch with Curegenix

    Copyright 2021 Curegenix Corporation | All Rights Reserved

    Curegenix